Crofelemer not checked
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total · 2 in the EU
What this is
- How it works
- Antidiarrheal FDA class
- Tested for
- Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases, Short Bowel Syndrome, Malabsorption Syndromes, Short Gut Syndrome, Post-Op Complication, Functional Gastrointestinal Disorders
- Main trialPhase 2/3
- “A study that will evaluate the safety, tolerability and preliminary efficacy of multiple ascending doses of crofelemer, compared to placebo, using a randomized cross-over design within each dose level, when administered to participants with MVID receiving parenteral support (PS, defined as TPN with or without supplementary IV fluid requirements). Blinded study drug will be administered as a novel crofelemer formulation, Crofelemer Powder for Oral Solution, or a matching placebo powder formulation for oral solution. Assigned study drug will be reconstituted and administered orally (or…”In the company’s words, NCT06721871 on ClinicalTrials.gov
Other drugs for Rare Diseases
Coming up2
- DecPhase 2/3 trial completes · ClinicalTrials.gov
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | Dec 2026 | Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID) | |
| Phase 2Recruiting | Mar 2027 | Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC) | |
| Phase 3Completed | 7 Aug 2023 | Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026